Proteome pulls out of prostate test

By Dylan Bushell-Embling
Tuesday, 15 July, 2008

Proteome Systems [ASX: PXL] has stopped development of a prostate cancer diagnostics test, after concluding that bringing the product to market would take too long.

Proteome had discovered cancerous prostate tissues demonstrate increased expression of Human Carcinoma Antigen [HCA], and developed an assay for detection of HCA in semen samples.

But the company concluded that developing the assay for commercialisation would take too long and consume too many resources.

A spokesperson for the company said Proteome was committed to projects with near-term revenue potential.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd